Research page
CJC/Ipa Blend

Specification
| Name | CJC/Ipa Blend |
|---|---|
| Catalog sizes | 5 mg/5 mg |
| Adopted bacteriostatic water | 10 mg + 2.0 mL = 5 mg/mL |
Overview
CJC/Ipa Blend places, on the TRACE label, 5 mg of CJC-1295 and 5 mg of ipamorelin (10 mg total). They are two different secretagogues of the growth-hormone axis: one related to GHRH and one to secretagogue (ghrelin) receptors. They stimulate a signal; they do not replace growth hormone.
Mechanism under study
CJC-1295 has been studied as a GHRH analog. The DAC (drug-affinity complex) form lengthens its presence in blood in the published work. Ipamorelin has been described as a pentapeptide selective for the secretagogue receptor, with less accompanying cortisol and prolactin release than older secretagogues in the laboratory reports cited.
What published research has reported
A 2006 study in The Journal of Clinical Endocrinology & Metabolism evaluated CJC-1295, the long-acting analog, in healthy adults and described a sustained rise in growth hormone and IGF-1 during the observation period. It is not a study of this blend.
Ipamorelin was presented in the European Journal of Endocrinology in 1998 as a selective secretagogue in laboratory models. TRACE does not turn that paper into a schedule.
Composition and mass
Label: 5 mg / 5 mg, 10 mg total. The adopted sheet uses 2 mL of bacteriostatic water (5 mg/mL of the total). If the label split is exact, each peptide sits at 2.5 mg/mL. That arithmetic is not a recommended amount.
Reconstitution
| mg | mL | mg/mL | |
|---|---|---|---|
| 10 | 2.0 | 5 | In the catalog |
Storage and handling
Lyophilized material cool, dry, and protected from light. Dissolved: refrigerate at 2–8 °C, do not freeze, 28-day horizon.
Regulatory status
Research material. It is not growth hormone, not a medicine approved for a general use, and not a supplement. The statements on this page have not been evaluated by the FDA.